内皮-间质转化在肾脏纤维化中的作用
本文综述内皮-间质转化(endMT)在肾脏纤维化中的作用:内皮细胞获得间质表型可扩充肌成纤维细胞池,并导致毛细血管稀疏与组织缺氧加重;AKI后修复不完全及继发纤维化反应是CKD发生的重要 contributor。TGF-β经经典/Smad介导与非经典通路被视为主要驱动因素,非TGF-β通路(炎症因子、代谢改变)亦可触发endMT;现有抗糖尿病药物或他汀类部分降低TGF-β信号可能具治疗潜力,但需进一步研究验证。
要点
- endMT使内皮细胞获得间质表型,可贡献肌成纤维细胞池并致毛细血管稀疏、缺氧加重
- AKI后微循环改变尤其endMT作为适应不良反应,可能与CKD发展相关
- TGF-β经典/非经典通路为主要驱动,非TGF-β通路亦可触发endMT
核心结论
- endMT作为适应不良反应可能参与肾脏纤维化及AKI-CKD进展,其相关细胞交互与信号通路为潜在治疗靶点。
- 目前部分降低TGF-β信号(抗糖尿病药物或他汀类)可能在肾脏情境具治疗潜力,但需进一步研究验证机制与临床获益。
研究设计与样本
- 综述:围绕肾脏纤维化中内皮-间质转化(endMT)的机制与治疗潜力进行论述。
主要发现
- 肌成纤维细胞为主要ECM产生细胞,可源于损伤后多种分化细胞类型。
- endMT描述内皮细胞向完全间质身份的表型转变,可能贡献纤维化中肌成纤维细胞池,同时导致毛细血管稀疏与组织缺氧加重。
- 肾脏疾病中,AKI恢复不完全及随之的纤维化反应是CKD发展的重要 contributor。
- TGF-β信号经经典/Smad介导与非经典通路下游激活,被视为该过程的主要驱动因素;涉及炎症因子与组织微环境细胞间代谢改变的非TGF-β通路亦可触发endMT。
临床怎么用
- 原文提出针对有害的适应不良细胞-细胞交互与信号通路,可能为阻碍endMT、减缓纤维化(如AKI-CKD进展)的治疗干预靶点。
- 原文指出目前使用抗糖尿病药物或他汀类部分降低TGF-β信号可能在肾脏情境具治疗潜力。
- 原文强调仍需进一步研究以验证机制并在临床框架内评估正面效应。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibrotic diseases are characterized by the uncontrolled accumulation of extracellular matrix (ECM) components leading to disruption of tissue homeostasis. Myofibroblasts as the main ECM-producing cells can originate from various differentiated cell types after injury. Particularly, the process of endothelial-to-mesenchymal transition (endMT), describing phenotypic shifts of endothelial cells to adopt a fully mesenchymal identity, may contribute to the pool of myofibroblasts in fibrosis, while leading to capillary rarefaction and exacerbation of tissue hypoxia. In renal disease, incomplete recovery from acute kidney injury (AKI) and the ensuing fibrotic reaction stand out as major contributors to chronic kidney disease (CKD) development. While the focus has largely been on impaired tubular epithelial repair as a potential fibrosis-driving mechanism, alterations in the renal microcirculation post-AKI, and in particular endMT as a maladaptive response, could hold equal significance. Dysfunctional interplays among various cell types in the kidney microenvironment can instigate endMT. Transforming growth factor beta (TGF-β) signaling, with its downstream activation of canonical/Smad-mediated and non-canonical pathways, has been identified as primary driver of this process. However, non-TGF-β-mediated pathways involving inflammatory agents and metabolic shifts in intercellular communication within the tissue microenvironment can also trigger endMT. These harmful, maladaptive cell-cell interactions and signaling pathways offer potential targets for therapeutic intervention to impede endMT and decelerate fibrogenesis such as in AKI-CKD progression. Presently, partial reduction of TGF-β signaling using anti-diabetic drugs or statins may hold therapeutic potential in renal context. Nevertheless, further investigation is warranted to validate underlying mechanisms and assess positive effects within a clinical framework.
引用
- Jacobs ME, de Vries DK, Engelse MA, et al. Endothelial to mesenchymal transition in kidney fibrosis. Nephrol Dial Transplant. 2024. PMID: 37968135. doi:10.1093/ndt/gfad238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。